Monomorphic epitheliotropic intestinal T-cell lymphoma presenting as acute small intestinal perforation: a case report and exploratory BCL-2–targeted therapy - Scorecard - MDSpire
Advertisement
Monomorphic epitheliotropic intestinal T-cell lymphoma presenting as acute small intestinal perforation: a case report and exploratory BCL-2–targeted therapy
Clinical Scorecard: Acute Small Intestinal Perforation as a Presentation of Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma: A Case Study and Investigation of BCL-2 Inhibition Therapy
At a Glance
Category
Detail
Condition
Key Mechanisms
High expression of anti-apoptotic proteins, such as Bcl-2; mutations in SETD2, STAT5B, and JAK3 affecting JAK/STAT signaling (source needed).
Target Population
Care Setting
Key Highlights
MEITL is a rare and aggressive lymphoma often presenting as a surgical emergency.
Diagnosis relies on histopathology and immunophenotyping (CD3+, CD8+, CD56+).
The patient achieved complete metabolic remission with Venetoclax and CHOP after initial treatment refusal.
Guideline-Based Recommendations
Diagnosis
Histopathology and immunohistochemistry are essential for diagnosis.
Characteristic immunophenotype includes CD3+, CD8+, CD56+.
Management
Emergency surgery for perforation is often required.
Consideration for BCL-2 inhibition therapy in high Bcl-2 expressing cases (source needed).
Monitoring & Follow-up
Postoperative PET/CT for assessing disease response and remission.
Risks
High resistance to conventional chemotherapy like CHOP.
Patient & Prescribing Data
72-year-old male with MEITL presenting with acute perforation.
Received Venetoclax (200 mg/day, days 1–14) combined with CHOP, achieving complete metabolic remission.
Clinical Best Practices
Utilize comprehensive immunohistochemistry for accurate diagnosis.
Consider the role of BCL-2 inhibitors in treatment regimens for MEITL (source needed).
